Biktarvy, formally known as bictegravir sulfate, represents a effective single-tablet regimen for controlling HIV infection. This drug combines three key antiviral drugs: bictegravir, emtricitabine, and tenofovir alafenamide. It operates by inhibiting the HIV's ability to copy within the body, remarkably decreasing the viral quantity. For many in